Umbrella review finds no tuberculosis biomarker meets WHO accuracy targets
- **An umbrella review of 46 systematic reviews found that no host or pathogen-derived biomarker consistently met World Health Organization target product profile accuracy thresholds for detecting, predicting progression of, or monitoring tuberculosis treatment.
- The analysis included 46 reviews: 40 on detection, seven on progression, and six on treatment monitoring, with some addressing multiple use cases.
- For detection, evidence was strongest for host proteins, host transcriptomics, and pathogen antigens.
- For progression, evidence was strongest for host transcriptomics, particularly for short-term risk prediction.
The publication
**An umbrella review of 46 systematic reviews found that no host or pathogen-derived biomarker consistently met World Health Organization target product profile accuracy thresholds for detecting, predicting progression of, or monitoring tuberculosis treatment. While evidence was strongest for host proteins and transcriptomics in detection and short-term risk prediction, most primary studies carried a high risk of selection bias.**
Who the findings apply to
The authors searched MEDLINE, Web of Science, Global Index Medicus, and the Cochrane Library from inception to September 1, 2025. They included systematic reviews on host-derived and pathogen-derived biomarkers for three use cases: detection of disease, prediction of progression to disease, and treatment monitoring and optimization. Reviews confined to WHO-endorsed tests for approved use cases were excluded.
Why this matters
The review addresses fragmented evidence regarding numerous described tuberculosis biomarkers by synthesizing findings across nine biomarker classes. It aims to determine which markers have potential to improve individual and public health outcomes for disease detection, progression prediction, and treatment optimization.
What the study found
The analysis included 46 reviews: 40 on detection, seven on progression, and six on treatment monitoring, with some addressing multiple use cases. For detection, evidence was strongest for host proteins, host transcriptomics, and pathogen antigens. For progression, evidence was strongest for host transcriptomics, particularly for short-term risk prediction. Evidence for predicting clinical outcomes in treatment monitoring was scarce.
Across all use cases, no biomarkers consistently met WHO target product profile accuracy thresholds. Most primary studies were at high risk of selection bias, and accuracy estimates varied widely.
What the result does not establish
The authors note that most primary studies were at high risk of selection bias and accuracy estimates varied widely. They conclude that prospective head-to-head studies in representative populations are needed to determine which biomarkers have potential to improve individual and public health outcomes.
The review excluded reviews confined to WHO-endorsed tests for approved use cases, focusing instead on emerging or non-standardized markers.
Authors’ conclusion
“Most primary studies were at high risk of selection bias, and accuracy estimates varied widely. Prospective head-to-head studies in representative populations are needed to determine which biomarkers have potential to improve individual and public health outcomes.”
Study and sources
Biomarkers for tuberculosis detection, progression, and treatment optimisation: an umbrella review of systematic reviews
Systematic review / meta-analysis · Lancet Microbe · 2026-11-17
Sources and limitations
- PubMed record PMID 43044621 (PubMed / NLM · 2026-11-19)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.


